Summary & Overview
HCPCS Level II C9168: Injection, mirikizumab-mrkz, 1 mg
HCPCS Level II code C9168 designates the injection of mirikizumab-mrkz, measured per 1 mg. As a HCPCS Level II product code for a biologic injectable, it is used on medical claims to capture units of drug administered in outpatient and ambulatory settings. Nationally, precise coding for specialty biologics matters for accurate payment, utilization tracking, and patient cost-sharing calculations.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for mirikizumab-mrkz as an injectable biologic, common sites of service where the product is administered, and the elements that typically appear on service lines when billed. The publication summarizes benchmark considerations and policy updates relevant to HCPCS Level II drug coding and reimbursement frameworks. It also outlines expected claim components and reporting practices for clinicians and billing professionals.
This resource is written for a national audience and focuses on coding clarity, billing implications, and payer coverage context to support accurate claims submission and administrative consistency.
Billing Code Overview
HCPCS Level II code C9168 describes the injection of mirikizumab-mrkz, 1 mg. This entry represents a billed unit for administration of the biologic agent mirikizumab-mrkz, recorded per milligram dose.
-
Service type: Injectable biologic medication administration
-
Typical site of service: Ambulatory infusion or injection setting, outpatient clinic, or physician office
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate-to-severe plaque psoriasis or active inflammatory bowel disease (Crohn disease or ulcerative colitis) being treated with subcutaneous biologic therapy. Mirikizumab-mrkz is supplied as a product billed per milligram using C9168 for 1 mg units. The clinical workflow begins with a specialty clinic or infusion/injectable therapy suite visit. A prescriber (dermatologist, gastroenterologist, or specialty pharmacist) documents indication, prior therapies, and baseline screening (e.g., TB test, hepatitis panel). At the visit, nursing staff prepare and administer the subcutaneous injection(s) and observe the patient for immediate hypersensitivity for 15–30 minutes. Documentation in the chart includes medication lot number, dose administered (converted from units billed as C9168), injection site, patient tolerance, and any concurrent services (e.g., evaluation and management). Billing uses C9168 units to reflect the milligrams administered; facility or professional claims may append appropriate modifiers to indicate unusual circumstances, bilateral procedures do not apply, and any linked CPT for injection administration may be billed per payer policy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|